

REMARKS:

Support for the amendment to claim 1 is found throughout the instant specification and particularly at paragraph [0009] and Table 1. Support for the amendment to claim 2 is found throughout the instant specification and particularly at paragraphs [0071 and 0079]. Support for the amendment to claim 3 is found throughout the instant specification and particularly at paragraphs [0071 and 0079]. Support for the amendment to claim 7 is found throughout the instant specification and particularly at paragraph [0009] and Table 1. Support for the amendment to claim 8 is found throughout the instant specification and particularly at paragraph [0010] and Table 1. Support for the amendment to claim 9 is found throughout the instant specification and particularly at paragraphs [0207 and 0208]. Support for the amendment to claim 10 is found throughout the instant specification and particularly at paragraph [0204]. Accordingly, no new matter has been introduced by the amendments made herein.

Support for new claims 13 and 16 is found throughout the instant specification and particularly at paragraphs [0058, 0060, 0070, 0071, and 0079] and Example 1. Support for new claims 14 and 17 is found throughout the instant specification and particularly at paragraphs [0058, 0060, 0070, 0071, and 0079] and Example 1. Support for new claims 15 and 18 is found throughout the instant specification and particularly at paragraphs [0071 and 0079]. Support for new claim 19 is found throughout the instant specification and particularly at paragraphs [0207 and 0208]. Support for new claim 20 is found throughout the instant specification and particularly at paragraph [0204]. Accordingly, no new matter has been introduced with the new claims. Applicants respectfully request their entry into the instant application.

The amendments to the specification in paragraphs [0009] and [0010] were performed to correct readily recognizable typographical and/or grammatical errors. In particular, the misspelled abbreviation for "monocyte chemoattractant protein-4" was amended from "MDP-4" to "MCP-4" to reflect the correct spelling as found in paragraph [0228]. Similarly, the misspelled word "escalectin" was amended to "ecalectin" to reflect the correct spelling as found in paragraph [0228] and Table 1 at SEQ ID NO. 258. Finally, the phrase "that is differentially expressed in an antigen presenting cell" was

In re: ROBERTS et al.
USSN: 10/033,145
Filed: 5 November 2001
Page 8

deleted from paragraph [0010] because it is incorrectly repeated twice in row.

Accordingly, no new matter has been introduced by the amendments found in the replacement paragraphs. Applicants respectfully respect their entry into the instant application.


SUMMARY:

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

November 25, 2003

Date

A handwritten signature in cursive script, appearing to read "Jennifer D. Tousignant", is written over a horizontal line.

Jennifer D. Tousignant

Agent for Applicants

Registration No. 54,498

Telephone: (508) 270-2499

Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322